If this box remains here for more than 30 seconds, click this link to try again.
Industries
Functions
Home » Products & Services » Best Practice Database » Medical Affairs » Health Outcomes
Download FREE Excerpt
13 Info Graphics
15 Data Graphics
170+ Metrics
3 Narratives
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Buy Now
STUDY OVERVIEW With payers wielding so much influence on formulary access, pharmaceutical companies understand the importance of providing accurate and compelling health outcomes information to the payer community. And with the medical affairs function already involved in the dissemination of medical information, many pharma companies have turned to this function to aid in critical payer interactions.
However, medical affairs organizations often face challenges in the planning and management of payer engagement and market access activities. Best Practices, LLC undertook this benchmarking study to understand the role of medical affairs in critical payer interactions and to highlight strategies for building and maintaining effective relationships with payers. This study provides benchmarks around preferred payer interactions, field staff access and interaction frequency and medical affairs structure. This study includes segments for large and small companies and US only and global. KEY TOPICS
Effectiveness of Services in Product Lifecycle: It is critical for Medical Affairs groups to adjust to the needs of payers during every stage of the product lifecycle.
This study reflects the data of 29 survey responses from Medical Affairs leaders at 27 biopharmaceutical companies.
Industries Profiled: Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Chemical; Health Care Companies Profiled: Abbvie; Alkermes; AstraZeneca; Baxalta; Biogen; CSL Behring; Daiichi Sankyo; EMD Serono; Genentech; Genomic Health; Lundbeck; Incyte; Janssen; Medivation; Mesoblast; Novartis; Pacira Pharmaceuticals; Pfizer; Pharmacyclics; ProStrakan; Santen; Servier; Shire; Teva Pharmaceutical Industries Ltd; Upsher-Smith; ViiV Healthcare
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.
Top